Alerta

MULTIPLE-SAMPLE LATERAL FLOW SYSTEM, DEVICE AND METHOD FOR DETECTING BIOMARKERS

Resumen de: WO2026172292A1

The disclosed multiple-sample lateral flow system, device and method leverages multiple biological samples, lateral flow test and communication module (such as Bluetooth) for accurately detecting biomarkers related to one or more medical conditions. The multiple-sample lateral flow system comprises an integrated multiple test strip (IMTS) and device. The IMTS, configured to receive and process at least two biological samples, comprises first and second test zones configured to detect first and second sets of biomarkers specific to first and second biological samples that are indicative of at least one first medical condition, second medical condition. The device comprises a strip receiving unit to receive the integrated multiple test strip; an imaging sensor configured to capture images of the integrated multiple test strip; and a communication module configured to transmit the captured images to a processing unit for analysis and identification of the one or more medical conditions.

COMPLEX FORMATION OF DETECTOR MOLECULES FOR SIMULTANEOUS DETECTION OF MULTIPLE ANALYTES

Resumen de: WO2026171791A1

The disclosure relates to a system for multiplex detection of analytes by primary translatable complexes. This refers to complexes of an antigen-specific primary antibody and oligonucleotides are used to detect multiple antigens of interest in a simultaneous manner. The linkage between primary antibody and oligonucleotides is achieved by using avidin-biotin system. Each of the multiple complexes are formed in individual reaction tubes and added simultaneously to biological specimens. The presence of antigens can be identified via various options using complementary oligonucleotides. This allows a simultaneous detection of analytes.

MULTIMODAL LATERAL FLOW ASSAY SYSTEM FOR SENSITIVE AND QUANTITATIVE DETECTION OF INFLAMMATION MARKERS

Resumen de: US20260243762A1

0000 A multimodal lateral flow assay (LFA) system for non-invasive biomarker monitoring is provided. The system includes a multimodal LFA strip having a sample-loading region for receiving a biological sample, a conjugate region containing triple-mode probes, and a membrane zone with immobilized capture and secondary antibodies that form respective test and control lines upon binding the probes. The triple-mode probes generate colorimetric, fluorescence, and surface-enhanced Raman scattering (SERS) signals. A laser-emitting module illuminates the membrane zone to excite fluorescence and SERS responses, which are detected by one or more optical detection devices. A processor performs multimodal signal mapping by analyzing fluorescence and SERS outputs to determine the quantitative concentration of the biomarker in the sample. The system enables sensitive, quantitative, and non-invasive detection of biomarkers across multiple optical modalities.

WEARABLE DEVICE FOR EARLY DISEASE DETECTION

Resumen de: WO2026170288A1

Various embodiments of a wearable device for disease detection are described herein. The wearable devices include a plurality of layers including an adhesive layer for affixing the wearable device to a subject's skin and a plurality of patterned layers, each patterned layer having a sensing pattern defined thereon. When the patterned layers are assembled, the sensing patterns cooperate to define: inlet chambers adapted to receive sweat droplets, each inlet chamber having antibodies conjugated to a detection medium adapted to bind to a corresponding biomarker of interest in the sweat droplets, sensing chambers, each sensing chamber receiving the sweat droplets from at least one inlet chamber via a microchannel through capillary action and adapted to sense a corresponding biomarker of interest by binding at least a portion of the conjugate molecules associated with the corresponding biomarker, and a control chamber in fluid communication with the sensing chambers via outlet channels.

PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF AGE-RELATED MUSCULOSKELETAL DISORDERS

Resumen de: US20260240871A1

A composition includes a lysosomal ABCA1 inhibitor. The composition inhibits the transport of cellular ABCA1 to lysosomes or suppresses ABCA1 within lysosomes, by including the lysosomal ABCA1 inhibitor, thereby inhibiting lysosomal cholesterol accumulation and the production of senescence-associated secretory phenotype (SASP) factors. Therefore, the composition can be used for inhibit age-related inflammation, and prevent, improve or treat age-related musculoskeletal disorders.

RNA SIGNATURE TEST FOR DIAGNOSIS OF THORACIC AORTIC ANEURYSM DISEASE

Resumen de: WO2026174031A1

A method for identifying RNA patterns in diagnosis and treatment of thoracic aortic aneurysm disease includes performing RNA sequencing on samples; analyzing the RNA sequencing data with the performance of differential gene expression analysis focusing on differentially regulated pathways to reveal complex regulatory mechanisms; developing a machine learning model to integrate pathway-level interactions; and combining pathway- specific analysis of the RNA patterns with the machine learning model to generate predictions identifying patients likely to be susceptible to thoracic aortic aneurysm disease.

METHOD

Resumen de: US20260243781A1

A method of measuring oxidative stress in a cell or tissue sample, the method including the steps of: (i) treating the cell or tissue sample in a medium; (ii) collecting a portion of the medium; (iii) measuring amounts of glutathione in the cell or tissue sample; and (iv) measuring amounts of reactive oxygen species (ROS) in the media portion collected in step (ii), step (iii) being carried out immediately after steps (i) and (ii), and step (iv) being carried out simultaneously with step (iii) or within 6 hours of step (iii) including assay time if the collected media portion is stored at about 0-8° C. until step (iv) is carried out.

NOVEL INHIBITORS OF HISTONE METHYLTRANSFERASE NUCLEAR LOCALISATION

Resumen de: US20260242753A1

The present invention relates to novel therapeutic compositions and methods for treating cancer. In particular, the use of proteinaceous inhibitors, including novel bicyclic peptide inhibitors, for use in treating cancer.

MOLECULAR PROBE FUNCTIONALIZED ELEMENT

Resumen de: US20260243761A1

The present invention provides a molecular probe functionalized element comprising a solid base element, a first layer comprising a linker A, a second layer comprising a peptide compound, a third layer comprising a linker B, and a fourth layer comprising a molecular probe, wherein the peptide compound is covalently bound to the solid base element via linker A and the molecular probe is covalently bound to the peptide compound via linker B. The present invention also provides a process for preparing the molecular probe functionalized element and a device comprising the molecular probe functionalized element such as an optical biosensor. Further, the present invention provides a method for detecting a biomarker comprising a) bringing into contact the molecular probe functionalized element with a sample suspected to comprise a target analyte; b) detecting the biomarker based on an interaction between the molecular probe and the target analyte. The present invention also provides a use of the molecular probe functionalized element or of the device for one or more of: a companion diagnostic test; diagnosing Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor in a patient; monitoring of therapy of patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Diabetes, Huntington, Prion disease, or a tumor; and screening of drugs for the treatment of Alzheimer's disease, Parkinson's disease

GQ/11 Protein Peptidomimetics

Resumen de: US20260242759A1

0000 The present invention relates to G protein peptidomimetics, in particular Gprotein peptidomimetics, capable of stabilizing a GPCR, in particular a Gprotein-coupled receptor, in an active conformational state. The G protein peptidomimetics are derived from the α<5 >helix of Gαprotein or mini-Gprotein, in particular they arise from modifications of peptides comprising or consisting of the amino acid sequence set forth in SEQ ID NO:13 or SEQ ID NO:14. The invention further provides complexes of the G protein peptidomimetics and a GPCR, fusion polypeptides of a GPCR and the G protein peptidomimetics and compositions comprising the same. Further disclosed herein are uses of the G protein peptidomimetics, complexes, fusion polypeptides and compositions for determining the structure of a GPCR conformer, for screening for compounds capable of specifically binding to a GPCR conformer and as allosteric modulator of a GPCR and as a biosensor.

METHOD FOR CONTROLLING MEMBRANE POTENTIAL-DEPENDENT ION CHANNEL THROUGH TYPE I TASTE RECEPTORS (T1RS)

Resumen de: US20260240820A1

The present invention pertains to a method for controlling a membrane potential-dependent ion channel (VGSC or the like) through a type I taste receptor present in a nerve cell or the like. In the present invention, it has been found that an Aβ peptide, or a sweet amino acid or an umami substance specifically binds to a type I taste receptor on the surface of a nerve cell to exert an agonist-like or antagonist-like action, thereby amplifying or suppressing a VGSC active current.Moreover, with the binding of an Aβ peptide or the like to a type I taste receptor, the amplification of a VGSC active current occurs, the overactivity of nerve cells causing epileptiform attack occurs, and a large number of substances, which can effectively suppress the amplification of the VGSC active current, among ligand substances that specifically bind to the type I taste receptor, can be found.The present invention provides: a type I taste receptor-specific ligand substance that can control the amplification or suppression of a VGSC active current; and a pharmaceutical composition for preventing or treating various neurodegenerative diseases, such as Alzheimer's disease (AD), due to the amplification of a VGSC active current caused by the binding of an Aβ peptide or the like to a type I taste receptor. Moreover, a method for using, as a target receptor, a type I taste receptor present in a nerve cell or the like to screen a ligand substance for controlling a VGSC or the like in the cell is al

Predicting adverse events from immunotherapy

Resumen de: AU2026210844A1

The disclosure relates to methods of diagnosis and prognosis, compositions for immunotherapies, methods of improving said compositions, and immunotherapies using the same (e.g., T cells, non- T cells, TCR-based therapies, CAR-based therapies, bispecific T-cell engagers (BiTEs), and/or immune checkpoint blockade). ul u l

IMMUNE CELL-DERIVED SECRETOME

Resumen de: US20260243757A1

0000 There is provided a composition comprising a secretome obtained by culturing an immune progenitor cell in the presence of an agent that activates the immune cell progenitor to an activated immune cell. Also provided is a composition for use in tissue regeneration, a method of generating a macrophage-derived secretome, a method of screening a drug and a method of culturing a proliferative cell.

알츠하이머병에서 중간엽 줄기 세포를 이용한 뇌 구조 및 바이오마커 개선

Resumen de: AU2024406255A1

Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.

PEPTIDES BLOCKING AMYLOID FIBRIL GROWTH

Resumen de: EP4793283A1

The present invention belongs the field of biomedicine, namely, treating and preventing Parkinson's and Alzheimer's diseases. These diseases are characterized by the presence of amyloid fibrils that drive the pathology progression in the brains of affected individuals. The invention discloses peptides that block ends of amyloid fibrils and stop their growth.

3 Manufacturing Method of Three-Dimensional Dopaminergic Neuronal Organoid-Based Assemblies through Direct Transdifferentiation Reprogramming

Resumen de: KR20260125740A

본 발명은 직접교차분화 리프로그래밍을 통한 3차원 도파민성 신경세포 오가노이드 제조방법에 관한 것이다.

診断方法

Resumen de: WO2021089651A1

The current application relates to personalised nutrition methods, particularly to methods of determining whether a human subject would benefit from taking a urolithin supplement and methods for determining the treatment dose of a urolithin supplement for a human subject. Particularly methods comprising determining the level of urolithin or a urolithin conjugate in a biological fluid, such as a dried whole blood spot sample, a dried plasma spot, a m spot sample or a urine sample The current application also relates to systems for presenting whether a human subject would benefit from taking a urolithin supplement and for presenting the treatment dose of a urolithin supplement for a human subject. The current application also relates to computer implementation of methods of the invention.

ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF

Resumen de: WO2025076635A1

Described herein are anti-alpha-synuclein antibodies. More specifically, described herein are antibodies specific to serine 129 phosphorylated alpha-synuclein. Further described herein is the use of the anti alpha-synuclein antibodies for the treatment or diagnosis of a synucleinopathy. Further described are kits and compositions comprising the anti alpha-synuclein antibodies detecting alpha-synuclein in a sample.

新規な選択的ＡＣＫＲ２モジュレーター

Resumen de: WO2025027065A1

The application discloses selective chimeric chemokines and their use for selectively targeting atypical chemokine receptor 2 (ACKR2) in the treatment of an autoimmune, inflammatory, neurological, cardiovascular or proliferative disease or disorder in a subject and/or for use in improving the response of a subject to anticancer immunotherapy. The application further discloses pharmaceutical compositions comprising such selective chimeric chemokines and further provides methods of production and uses of said chimeric cytokines.

DETECTION OF DISEASE STATE MACROMOLECULES BINDING TO NORMAL MACROMOLECULES AS A BIOMARKER FOR DISEASE IDENTIFICATION

Resumen de: WO2025080894A1

In one aspect, the present disclosure provides a method of detecting a presence or absence of a biomarker for a disease in the sample, wherein the biomarker comprises: a) a complex of physiologically active target macromolecules or a fragment or portion thereof and target macromolecules that are not physiologically active; b) a conformation of the physiologically active macromolecules or fragment thereof when the physiologically active target macromolecules or the fragment or portion thereof is a complex with a non- physiologically active target macromolecule; c) the conformation of physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; d) the conformation of non-physiologically active target macromolecules or a portion or fragment thereof in a PAT-Tau complex; or e) a combination of a), b), c), d) and/or e).

一种用于阿尔茨海默病诊断的生物标志物组合及其检测试剂盒

Resumen de: CN122588234A

本发明公开了一种用于阿尔茨海默病诊断的生物标志物组合及其检测试剂盒，涉及生物医学及分子诊断技术领域，所述生物标志物组合包括检测以下基因或其编码蛋白的表达水平的试剂：胶质纤维酸性蛋白基因 GFAP、前蛋白转化酶1基因 PCSK1、可溶性耐药相关钙结合蛋白基因 SRI、SWI/SNF染色质重塑复合物亚基C1基因 SMARCC1、双特异性酪氨酸磷酸化调节激酶2基因 DYRK2 和神经肽Y基因 NPY。本发明的生物标志物组合不仅可在脑组织样本中实现有效检测，还可在外周血、血浆、血清或脑脊液等临床易于获取的样本中稳定检出，为阿尔茨海默病的大规模人群筛查和早期辅助诊断提供了一种无创、简便且易于推广的检测方案。

神経変性疾患の診断などを補助する方法、キット、バイオマーカーおよびバイオマーカーセット

Resumen de: JP2026132804A

0001 【課題】神経変性疾患の診断を補助する方法、およびアルツハイマー型認知症とパーキンソン病の鑑別を補助する方法；神経変性疾患の診断キット、およびアルツハイマー型認知症とパーキンソン病の鑑別キット；並びに神経変性疾患の診断用バイオマーカー、神経変性疾患の診断用バイオマーカーセット、およびアルツハイマー型認知症とパーキンソン病の鑑別用バイオマーカーセットを提供すること。 【解決手段】被検試料中の、細胞外小胞におけるＣＤ４１の量またはＣＤ６１の量を検出することを含む神経変性疾患の診断を補助する方法であって、上記ＣＤ４１の量またはＣＤ６１の量を含む指標が、神経変性疾患以外の対象よりも低いことが、神経変性疾患を示唆する、神経変性疾患の診断を補助する方法。 【選択図】なし

用于T细胞疗法的诊断方法

Resumen de: PH12017502153A1

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

用于磷酸化Tau蛋白pTau181检测的抗体、免疫检测方法及应用

Resumen de: CN122587066A

本申请公开了一种用于磷酸化Tau蛋白pTau181检测的抗体、免疫检测方法及应用。本申请抗体包括T181‑1B4抗体；T181‑1B4的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau181进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau181快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau181磷酸化相关检测具有重要意义。

Tau蛋白免疫传感器及其制备方法

Nº publicación: CN122591958A 18/08/2026

Solicitante:

宁夏医科大学

Resumen de: CN122591958A

0001 本发明提供了Tau蛋白免疫传感器及其制备方法，其中，Tau蛋白免疫传感器的制备方法包括：使锰掺杂二硫化钼与金源以获得金纳米粒子‑锰掺杂二硫化钼复合体；使含有所述金纳米粒子‑锰掺杂二硫化钼复合体的悬浮液覆盖丝网印刷电极上，以在所述丝网印刷电极的表面形成复合体层；S3：在所述复合体层上覆盖抗Tau蛋白抗体溶液并孵育至少1小时，然后洗去多余抗Tau蛋白抗体溶液，得到抗Tau蛋白抗体层；及S4：封闭抗Tau蛋白抗体层上的非特异性结合位点，得到所述Tau蛋白检测传感器。根据试验确定，本发明构建的Tau蛋白免疫传感器的检测限可以低至20fM。